February 25, 2014
The ongoing Molybdenum-99 (Mo-99) supply challenges faced by the nuclear medicine industry remain in effect. Based on currently available resources and projections for Mo-99 supply, generator standing orders should be met throughout March. As always, this information is subject to change. Given the evolving situation, it is premature to project supply beyond March. Mallinckrodt recognizes the effect of these supply challenges in the instances when you and the patients you serve are affected.
Click here for the full letter from Mallinckrodt Pharmaceuticals.